Literature DB >> 21030121

Venous access in the management of hemophilia.

Leonard A Valentino1, Mohammad Kawji, Michele Grygotis.   

Abstract

Venous access is an essential aspect of hemophilia care. When peripheral venipuncture is not feasible, central venous access devices (CVADs) or the creation of an arteriovenous fistula (AVF) allow the infusion of clotting factor concentrate to treat or prevent bleeding events or eliminate inhibitors. Infection is the primary complication associated with CVADs and the most common reason for their removal. Complications of AVF include occlusion and limb length discrepancies.
Copyright © 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 21030121     DOI: 10.1016/j.blre.2010.10.001

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  3 in total

1.  Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.

Authors:  K John Pasi; Toshko Lissitchkov; Vasily Mamonov; Tim Mant; Margarita Timofeeva; Catherine Bagot; Pratima Chowdary; Pencho Georgiev; Liana Gercheva-Kyuchukova; Kate Madigan; Huy Van Nguyen; Qifeng Yu; Baisong Mei; Craig C Benson; Margaret V Ragni
Journal:  J Thromb Haemost       Date:  2021-05-18       Impact factor: 5.824

2.  Comparative N-Glycosylation Analysis of the Fc Portions of a Chimeric Human Coagulation Factor VIII and Immunoglobulin G1.

Authors:  Christoph Kannicht; Mario Kröning; Barbara A Solecka-Witulska; Guido Kohla; Julia Rosenlöcher
Journal:  Bioengineering (Basel)       Date:  2017-05-17

Review 3.  Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias.

Authors:  Maria Elisa Mancuso; Pier Mannuccio Mannucci
Journal:  Drug Des Devel Ther       Date:  2014-03-28       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.